168 related articles for article (PubMed ID: 38017410)
1. Detection of continuous hierarchical heterogeneity by single-cell surface antigen analysis in the prognosis evaluation of acute myeloid leukaemia.
Shao N; Ren C; Hu T; Wang D; Zhu X; Li M; Cheng T; Zhang Y; Zhang XE
BMC Bioinformatics; 2023 Nov; 24(1):450. PubMed ID: 38017410
[TBL] [Abstract][Full Text] [Related]
2. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
3. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
5. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia.
Griffin JD; Davis R; Nelson DA; Davey FR; Mayer RJ; Schiffer C; McIntyre OR; Bloomfield CD
Blood; 1986 Dec; 68(6):1232-41. PubMed ID: 2946331
[TBL] [Abstract][Full Text] [Related]
6. Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia.
Aung MMK; Mills ML; Bittencourt-Silvestre J; Keeshan K
Mol Oncol; 2021 Sep; 15(9):2253-2272. PubMed ID: 33421304
[TBL] [Abstract][Full Text] [Related]
7. A single-cell survey of cellular hierarchy in acute myeloid leukemia.
Wu J; Xiao Y; Sun J; Sun H; Chen H; Zhu Y; Fu H; Yu C; E W; Lai S; Ma L; Li J; Fei L; Jiang M; Wang J; Ye F; Wang R; Zhou Z; Zhang G; Zhang T; Ding Q; Wang Z; Hao S; Liu L; Zheng W; He J; Huang W; Wang Y; Xie J; Li T; Cheng T; Han X; Huang H; Guo G
J Hematol Oncol; 2020 Sep; 13(1):128. PubMed ID: 32977829
[TBL] [Abstract][Full Text] [Related]
8. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF).
Maag AH; Swanton H; Kull M; Vegi NM; Feuring M
Cytometry A; 2023 Jul; 103(7):551-562. PubMed ID: 36647792
[TBL] [Abstract][Full Text] [Related]
10. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
11. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
Mumme H; Thomas BE; Bhasin SS; Krishnan U; Dwivedi B; Perumalla P; Sarkar D; Ulukaya GB; Sabnis HS; Park SI; DeRyckere D; Raikar SS; Pauly M; Summers RJ; Castellino SM; Wechsler DS; Porter CC; Graham DK; Bhasin M
Nat Commun; 2023 Oct; 14(1):6209. PubMed ID: 37798266
[TBL] [Abstract][Full Text] [Related]
12. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity.
Cross AH; Goorha RM; Nuss R; Behm FG; Murphy SB; Kalwinsky DK; Raimondi S; Kitchingman GR; Mirro J
Blood; 1988 Aug; 72(2):579-87. PubMed ID: 3261183
[TBL] [Abstract][Full Text] [Related]
14. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
[TBL] [Abstract][Full Text] [Related]
15. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS; Porter CC; Castellino SM; Graham DK; Bhasin M
Genome Med; 2023 Oct; 15(1):83. PubMed ID: 37845689
[TBL] [Abstract][Full Text] [Related]
17. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in acute myeloid leukemia.
Gerhartz HH; Schmetzer H
Leukemia; 1990 Jul; 4(7):508-16. PubMed ID: 1695705
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.
Fu Y; Xu M; Cui Z; Yang Z; Zhang Z; Yin X; Huang X; Zhou M; Wang X; Chen C
EBioMedicine; 2020 Feb; 52():102664. PubMed ID: 32062360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]